
Multiple myeloma (MM) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051124

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines details of PBS-subsidised lenalidomide and
pomalidomide for patients with multiple myeloma (MM).

MM and listing dates

MM is a type of blood cancer.

Listing dates:

-   lenalidomide - 1 November 2009
-   pomalidomide - 1 August 2015
-   elotuzumab – 1 May 2022

See Written Authority Required Drugs for more information.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, contact details,
item and restriction codes, the PBS schedule and the Services Australia
website.

Related links

Contacting a Health Service Delivery Division Programme Support Officer
(PSO)

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Processing and National Demand Allocation (PaNDA)

Process telephone Authority approval application

Process written authority approval requests

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
